Head-To-Head Survey: Synlogic (SYBX) & BioMarin Pharmaceutical (BMRN)

Synlogic (NASDAQ: SYBX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares Synlogic and BioMarin Pharmaceutical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Synlogic N/A N/A -$26.26 million ($9.43) -1.09
BioMarin Pharmaceutical $1.12 billion 14.01 -$630.21 million ($0.83) -107.37

Synlogic has higher earnings, but lower revenue than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Synlogic N/A -50.19% -46.76%
BioMarin Pharmaceutical -12.45% -4.60% -3.09%

Analyst Ratings

This is a summary of current recommendations and price targets for Synlogic and BioMarin Pharmaceutical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synlogic 0 1 2 0 2.67
BioMarin Pharmaceutical 0 5 15 1 2.81

Synlogic presently has a consensus target price of $19.67, suggesting a potential upside of 91.87%. BioMarin Pharmaceutical has a consensus target price of $114.11, suggesting a potential upside of 28.04%. Given Synlogic’s higher possible upside, equities research analysts clearly believe Synlogic is more favorable than BioMarin Pharmaceutical.

Insider and Institutional Ownership

64.2% of Synlogic shares are owned by institutional investors. Comparatively, 99.2% of BioMarin Pharmaceutical shares are owned by institutional investors. 18.6% of Synlogic shares are owned by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Synlogic has a beta of 3.17, indicating that its share price is 217% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Summary

BioMarin Pharmaceutical beats Synlogic on 8 of the 14 factors compared between the two stocks.

About Synlogic

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.